BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chabi A, Zhang Y, Jackson S, Cady R, Lines C, Herring WJ, Connor KM, Michelson D. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia 2015;35:379-88. [PMID: 25106663 DOI: 10.1177/0333102414544979] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Karsan N, Bose P, Goadsby PJ. The Migraine Premonitory Phase. Continuum (Minneap Minn) 2018;24:996-1008. [PMID: 30074545 DOI: 10.1212/CON.0000000000000624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Holland PR. Biology of Neuropeptides: Orexinergic Involvement in Primary Headache Disorders. Headache 2017;57 Suppl 2:76-88. [PMID: 28485849 DOI: 10.1111/head.13078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
3 Goadsby PJ. Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients. Brain 2016;139:2571-7. [PMID: 27671024 DOI: 10.1093/brain/aww236] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
4 Tfelt-hansen P, Lindqvist JK, Do TP. Evaluating the reporting of adverse events in controlled clinical trials conducted in 2010–2015 on migraine drug treatments. Cephalalgia 2018;38:1885-95. [DOI: 10.1177/0333102418759785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Spasov AA, Yakovlev DS, Brigadirova AA, Maltsev DV, Agatsarskaya YV. Novel Approaches to the Development of Antimigraine Drugs: A Focus on 5-HT2A Receptor Antagonists. Russ J Bioorg Chem 2019;45:76-88. [DOI: 10.1134/s1068162019020146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Flores Á, Saravia R, Maldonado R, Berrendero F. Orexins and fear: implications for the treatment of anxiety disorders. Trends in Neurosciences 2015;38:550-9. [DOI: 10.1016/j.tins.2015.06.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
7 Robbins NM, Bernat JL. Minority Representation in Migraine Treatment Trials. Headache 2017;57:525-33. [PMID: 28127754 DOI: 10.1111/head.13018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
8 Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. Pharmacology & Therapeutics 2018;186:25-44. [DOI: 10.1016/j.pharmthera.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
10 Vécsei L, Lukács M, Tajti J, Fülöp F, Toldi J, Edvinsson L. The Therapeutic Impact of New Migraine Discoveries. Curr Med Chem 2019;26:6261-81. [PMID: 29848264 DOI: 10.2174/0929867325666180530114534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kooshki R, Abbasnejad M, Esmaeili-mahani S, Raoof M, Sheibani V. Activation orexin 1 receptors in the ventrolateral periaqueductal gray matter attenuate nitroglycerin-induced migraine attacks and calcitonin gene related peptide up-regulation in trigeminal nucleus caudalis of rats. Neuropharmacology 2020;178:107981. [DOI: 10.1016/j.neuropharm.2020.107981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Valade D. [New horizons for acute and prophylactic treatments of migraine]. Biol Aujourdhui 2019;213:59-64. [PMID: 31274104 DOI: 10.1051/jbio/2019021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Cai Z, Liu H, Wang L, Li X, Bai L, Gan X, Li L, Han C. Molecular Evolutionary Analysis of the HCRTR Gene Family in Vertebrates. Biomed Res Int 2018;2018:8120263. [PMID: 29967787 DOI: 10.1155/2018/8120263] [Reference Citation Analysis]
14 Ogunlaja O, Karsan N, Goadsby P. Emerging drugs for the prevention of migraine. Expert Opin Emerg Drugs 2021;26:271-80. [PMID: 34263680 DOI: 10.1080/14728214.2021.1956463] [Reference Citation Analysis]
15 Levine A, Vanderah TW, Largent-Milnes TM. An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine. Cephalalgia 2021;41:404-16. [PMID: 33131303 DOI: 10.1177/0333102420966984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Waliszewska-Prosół M, Nowakowska-Kotas M, Chojdak-Łukasiewicz J, Budrewicz S. Migraine and Sleep-An Unexplained Association? Int J Mol Sci 2021;22:5539. [PMID: 34073933 DOI: 10.3390/ijms22115539] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol 2015;14:1010-22. [PMID: 26376968 DOI: 10.1016/S1474-4422(15)00198-2] [Cited by in Crossref: 100] [Cited by in F6Publishing: 33] [Article Influence: 14.3] [Reference Citation Analysis]
18 Chow M, Cao M. The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress. Nat Sci Sleep 2016;8:81-6. [PMID: 27051324 DOI: 10.2147/NSS.S76711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
19 Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
20 Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 2017;97:553-622. [PMID: 28179394 DOI: 10.1152/physrev.00034.2015] [Cited by in Crossref: 570] [Cited by in F6Publishing: 485] [Article Influence: 114.0] [Reference Citation Analysis]
21 Tajti J, Szok D, Majláth Z, Tuka B, Csáti A, Vécsei L. Migraine and neuropeptides. Neuropeptides 2015;52:19-30. [DOI: 10.1016/j.npep.2015.03.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
22 Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. Springerplus 2016;5:637. [PMID: 27330903 DOI: 10.1186/s40064-016-2211-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
23 Goadsby PJ, Holland PR. Migraine Therapy: Current Approaches and New Horizons. Neurotherapeutics 2018;15:271-3. [PMID: 29667112 DOI: 10.1007/s13311-018-0626-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation. Biomedicine & Pharmacotherapy 2017;90:187-93. [DOI: 10.1016/j.biopha.2017.03.053] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
25 Pourrahimi AM, Abbasnejad M, Raoof M, Esmaeili-Mahani S, Kooshki R. The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats. Peptides 2021;146:170651. [PMID: 34560171 DOI: 10.1016/j.peptides.2021.170651] [Reference Citation Analysis]
26 Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol 2018;14:699-710. [DOI: 10.1038/s41582-018-0098-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 13.8] [Reference Citation Analysis]
27 Peroutka SJ. Clinical Trials Update 2014: Year in Review. Headache: The Journal of Head and Face Pain 2015;55:149-57. [DOI: 10.1111/head.12479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
28 Do TP, Al-Saoudi A, Ashina M. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants. Rev Neurol (Paris) 2021:S0035-3787(21)00610-X. [PMID: 34294458 DOI: 10.1016/j.neurol.2021.06.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Wei DY, Jensen RH. Therapeutic Approaches for the Management of Trigeminal Autonomic Cephalalgias. Neurotherapeutics 2018;15:346-60. [PMID: 29516437 DOI: 10.1007/s13311-018-0618-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
30 Silberstein SD. Current management: migraine headache. CNS Spectr 2017;22:1-13. [DOI: 10.1017/s1092852917000864] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
31 Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol 2016;12:635-50. [PMID: 27786243 DOI: 10.1038/nrneurol.2016.143] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 14.0] [Reference Citation Analysis]
32 May A, Burstein R. Hypothalamic regulation of headache and migraine. Cephalalgia 2019;39:1710-9. [PMID: 31466456 DOI: 10.1177/0333102419867280] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
33 Berger A, Litwin J, Allen IE, Qubty W, Irwin S, Waung M, Gelfand AA. Preliminary Evidence that Melatonin Is not a Biomarker in Children and Adolescents With Episodic Migraine. Headache 2019;59:1014-23. [PMID: 31054199 DOI: 10.1111/head.13547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Mcdonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. Journal of Neurogenetics 2016;30:32-41. [DOI: 10.3109/01677063.2016.1171862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
36 Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. Targets for migraine treatment: beyond calcitonin gene-related peptide. Curr Opin Neurol 2021;34:363-72. [PMID: 33840777 DOI: 10.1097/WCO.0000000000000935] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35:6619-6629. [PMID: 25926442 DOI: 10.1523/jneurosci.0373-15.2015] [Cited by in Crossref: 317] [Cited by in F6Publishing: 123] [Article Influence: 45.3] [Reference Citation Analysis]
38 Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab 2019;39:573-94. [PMID: 28948863 DOI: 10.1177/0271678X17733655] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
39 Karsan N, Goadsby PJ. Migraine: beyond pain. Pract Neurol 2021;21:475-80. [PMID: 34556570 DOI: 10.1136/practneurol-2020-002844] [Reference Citation Analysis]
40 Akerman S, Romero-reyes M, Holland PR. Current and novel insights into the neurophysiology of migraine and its implications for therapeutics. Pharmacology & Therapeutics 2017;172:151-70. [DOI: 10.1016/j.pharmthera.2016.12.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
41 Ferroni P, Barbanti P, Della-Morte D, Palmirotta R, Jirillo E, Guadagni F. Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions. Antioxid Redox Signal 2018;28:1144-83. [PMID: 28990418 DOI: 10.1089/ars.2017.7260] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
42 Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, Hubalek IA, Marchenko Y, Overeem LH, Piroso S, Tkachev A, Martelletti P, Sacco S; European Headache Federation School of Advanced Studies (EHF-SAS). Migraine and sleep disorders: a systematic review. J Headache Pain 2020;21:126. [PMID: 33109076 DOI: 10.1186/s10194-020-01192-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
43 Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, Zhang W, Zhang J, Chen Z, Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2021;61:101573. [PMID: 34902823 DOI: 10.1016/j.smrv.2021.101573] [Reference Citation Analysis]
44 Strother LC, Srikiatkhachorn A, Supronsinchai W. Targeted Orexin and Hypothalamic Neuropeptides for Migraine. Neurotherapeutics 2018;15:377-90. [PMID: 29442286 DOI: 10.1007/s13311-017-0602-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
45 Joseph Herring W, Ge JY, Jackson S, Assaid C, Connor KM, Michelson D. Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant. Clin J Pain 2018;34:37-43. [PMID: 28448426 DOI: 10.1097/AJP.0000000000000503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol 2017;264:2031-9. [PMID: 28321564 DOI: 10.1007/s00415-017-8434-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 11.2] [Reference Citation Analysis]
47 Lambru G, Andreou AP, Guglielmetti M, Martelletti P. Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs 2018;23:301-18. [PMID: 30484333 DOI: 10.1080/14728214.2018.1552939] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
48 Askari-Zahabi K, Abbasnejad M, Kooshki R, Esmaeili-Mahani S. Orexin one receptors within the basolateral amygdala are involved in the modulation of cognitive deficits associated with a migraine-like state in rats. Neurol Res 2021;:1-11. [PMID: 34233602 DOI: 10.1080/01616412.2021.1949687] [Reference Citation Analysis]
49 Ashina M, Doležil D, Bonner JH, Zhou L, Klatt J, Picard H, Mikol DD. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 2021;41:33-44. [PMID: 33231489 DOI: 10.1177/0333102420970889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
50 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
51 Barloese MCJ. The pathophysiology of the trigeminal autonomic cephalalgias, with clinical implications. Clin Auton Res 2018;28:315-24. [DOI: 10.1007/s10286-017-0468-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Bertels Z, Pradhan AAA. Emerging Treatment Targets for Migraine and Other Headaches. Headache 2019;59 Suppl 2:50-65. [PMID: 31291018 DOI: 10.1111/head.13585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]